Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis

Target: PRKAA1/PPARGC1A Composite Score: 0.000 Price: $0.00 Citation Quality: Pending developmental neurobiology Status: proposed Variant of Microglial Metabolic Trained Immunity via mTOR-HIF
☰ Compare⚔ Duel⚛ Collideinteract with this hypothesis
✓ All Quality Gates Passed
Evidence Strength Pending (0%)
0
Citations
1
Debates
3
Supporting
2
Opposing
Quality Report Card click to collapse
F
Composite: 0.000
Top 50% of 1512 hypotheses
T4 Speculative
Novel AI-generated, no external validation
Needs 1+ supporting citation to reach Provisional
B Mech. Plausibility 15% 0.65 Top 48%
F Evidence Strength 15% 0.00 Top 50%
F Novelty 12% 0.00 Top 50%
F Feasibility 12% 0.00 Top 50%
F Impact 12% 0.00 Top 50%
A Druggability 10% 0.82 Top 21%
D Safety Profile 8% 0.38 Top 87%
B+ Competition 6% 0.70 Top 38%
B Data Availability 5% 0.62 Top 50%
B Reproducibility 5% 0.68 Top 31%
Evidence
3 supporting | 2 opposing
Citation quality: 0%
Debates
1 session B+
Avg quality: 0.71
Convergence
0.00 F 12 related hypothesis share this target

From Analysis:

Do perinatal immune challenges create persistent epigenetic modifications that prime microglia for AD decades later?

The debate raised this developmental hypothesis but couldn't resolve the mechanistic link between early-life immune events and late-onset neurodegeneration. This represents a fundamental gap in understanding AD's developmental origins. Source: Debate session sess_SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404 (Analysis: SDA-2026-04-04-gap-neuro-microglia-early-ad-20260404)

→ View full analysis & debate transcript

Description

The astrocytic metabolic trained immunity hypothesis proposes that perinatal immune activation fundamentally reprograms astrocytic cellular metabolism through the AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) signaling axis. Upon exposure to PAMPs or DAMPs during critical developmental windows, astrocytic pattern recognition receptors, including TLR3 and TLR4, initiate calcium-dependent signaling cascades that activate calcium/calmodulin-dependent protein kinase kinase β (CaMKKβ), which subsequently phosphorylates and activates AMPK at threonine 172. Activated AMPK phosphorylates PGC1α at multiple serine residues (Ser538, Ser568), promoting its nuclear translocation and transcriptional coactivator function.

...

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

flowchart TD
    A["Danger Signal
Abeta / LPS Priming"] B["mTOR Complex 1 Activation
Nutrient and Stress Sensor"] C["HIF-1alpha Stabilization
Hypoxia-Response Gene Program"] D["Trained Immunity Epigenetic Mark
H3K4me3 at Inflammatory Loci"] E["Exaggerated Cytokine Response
Re-challenge Hyperactivation"] F["Neuroinflammatory Bystander Damage
Synaptic / Neuronal Loss"] G["Rapamycin / mTOR Inhibitor
Reset Trained Immunity"] A --> B B --> C C --> D D --> E E --> F G -.->|"blocks"| B style A fill:#7b1fa2,stroke:#ce93d8,color:#ce93d8 style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a style G fill:#1b5e20,stroke:#81c784,color:#81c784

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for PRKAA1/PPARGC1A from GTEx v10.

Cerebellar Hemisphere22.3 Cerebellum18.0 Spinal cord cervical c-115.7 Hypothalamus11.4 Substantia nigra9.7 Frontal Cortex BA99.2 Nucleus accumbens basal ganglia8.3 Caudate basal ganglia8.1 Hippocampus7.6 Cortex7.4 Anterior cingulate cortex BA247.0 Putamen basal ganglia6.9 Amygdala6.5median TPM (GTEx v10)

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.
Mechanistic 0.65 (15%) Evidence 0.00 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.82 (10%) Safety 0.38 (8%) Competition 0.70 (6%) Data Avail. 0.62 (5%) Reproducible 0.68 (5%) KG Connect 0.50 (8%) 0.000 composite
5 citations 5 with PMID Validation: 0% 3 supporting / 2 opposing
For (3)
No supporting evidence
No opposing evidence
(2) Against
High Medium Low
High Medium Low
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
1
MECH 4CLIN 1GENE 0EPID 0
ClaimStanceCategorySourceStrength ↕Year ↕Quality ↕PMIDsAbstract
HIF1α drives glycolysis in pro-inflammatory macrop…SupportingMECH----PMID:20876827-
Microglia display metabolic shifts in AD modelsSupportingMECH----PMID:30550822-
Trained immunity in monocytes is mTOR-dependentSupportingMECH----PMID:28473586-
Teratogenicity of mTOR inhibitors makes perinatal …OpposingCLIN----PMID:N/A-
Metabolic reprogramming may not persist for decade…OpposingMECH----PMID:N/A-
Legacy Card View — expandable citation cards

Supporting Evidence 3

HIF1α drives glycolysis in pro-inflammatory macrophages
Microglia display metabolic shifts in AD models
Trained immunity in monocytes is mTOR-dependent

Opposing Evidence 2

Teratogenicity of mTOR inhibitors makes perinatal intervention contraindicated
Metabolic reprogramming may not persist for decades without ongoing stimulus
Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬 Theorist Proposes novel mechanisms and generates creative hypotheses

Mechanistic Hypotheses: Perinatal Immune Priming and Alzheimer's Disease

Hypothesis 1: TREM2 Promoter Silencing via DNA Hypermethylation

Mechanism: Maternal immune activation (MIA) during critical developmental windows induces DNA hypermethylation at the TREM2 promoter, creating life-long haploinsufficiency that impairs microglial amyloid clearance while preserving hyper-inflammatory responses.

Target: TREM2 (Triggering Receptor Expressed on Myeloid Cells 2)

Supporting Evidence:

  • TREM2 deficiency in microglia promotes amyloid plaque compaction but increases neurotoxicity

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns

Critical Evaluation of Perinatal Immune Priming Hypotheses in Alzheimer's Disease

Overview

These hypotheses propose mechanistic links between perinatal immune activation (MIA) and late-onset Alzheimer's disease via persistent microglial epigenetic modifications. I evaluate each for evidential strength, logical coherence, falsifiability, and translational plausibility.

Hypothesis 1: TREM2 Promoter Silencing via DNA Hypermethylation

Critical Weaknesses

Contradictory Directionality Problem
The mechanism conflates two distinct phenotypes: TREM2 deficiency actually *enhanc

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation

Feasibility Assessment: Perinatal Immune Priming Hypotheses in Alzheimer's Disease

Executive Summary

The seven mechanistic hypotheses proposing developmental origins for Alzheimer's disease via perinatal immune priming represent a sophisticated integration of neuroimmunology and epigenetics. Following critical evaluation of mechanistic plausibility, I assess the translational feasibility of those that warrant continued investigation, prioritizing those with the strongest mechanistic grounding and actionable therapeutic targets.

Primary Recommendation: The field should prioritize **

Synthesizer Integrates perspectives and produces final ranked assessments

{
"ranked_hypotheses": [
{
"title": "CX3CR1 Promoter Methylation Disrupts Neuron-Microglia Cross-Talk",
"description": "Perinatal cytokines (IL-6) induce lasting CpG methylation at the CX3CR1 promoter, reducing microglial CX3CR1 expression. This disrupts fractalkine signaling, impairing surveillance and removing the neuronal 'off signal,' leading to chronic neurotoxic microglial phenotypes in aging.",
"target_gene": "CX3CR1",
"dimension_scores": {
"evidence_strength": 0.72,
"novelty": 0.65,
"feasibility": 0.70,
"therapeutic_potentia

Price History

No price history recorded yet

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
Low
0.0000
Events (7d)
0

Clinical Trials (0)

No clinical trials data available

📚 Cited Papers (4)

Myocarditis during lenalidomide therapy.
The Annals of pharmacotherapy (2010) · PMID:20876827
No extracted figures yet
No extracted figures yet
No extracted figures yet
No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (0)

No notebooks linked to this analysis yet. Notebooks are generated when Forge tools run analyses.

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

mutate · gen 1
parent: h-cb1d193197
→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score
0.50
32.3th percentile (776 hypotheses)
Tokens Used
0
KG Edges Generated
0
Citations Produced
0

Cost Ratios

Cost per KG Edge
0.00 tokens
Lower is better (baseline: 2000)
Cost per Citation
0.00 tokens
Lower is better (baseline: 1000)
Cost per Score Point
0.00 tokens
Tokens / composite_score

Score Impact

Efficiency Boost to Composite
+0.050
10% weight of efficiency score
Adjusted Composite
0.050

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for PRKAA1/PPARGC1A.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for PRKAA1/PPARGC1A →

Related Hypotheses

Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis
Score: 0.000 | developmental neurobiology
CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming in Perinatal Neuroinflammation
Score: 0.000 | developmental neurobiology
CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Reprogramming in Autism
Score: 0.000 | developmental neurobiology
Astroglial Gating of Microglial Ontogeny Switch
Score: 0.000 | developmental neurobiology
Microglial Phenotypic Polarization via CSF1R-Mediated Metabolic Reprogramming
Score: 0.000 | developmental neurobiology

Estimated Development

Estimated Cost
$0
Timeline
0 months

🧪 Falsifiable Predictions

No explicit predictions recorded yet. Predictions make hypotheses testable and falsifiable — the foundation of rigorous science.

Knowledge Subgraph (0 edges)

No knowledge graph edges recorded

3D Protein Structure

🧬 PRKAA1 — PDB 4CFE Click to expand 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Do perinatal immune challenges create persistent epigenetic modifications that prime microglia for AD decades later?

developmental neurobiology | 2026-04-07 | archived

Community Feedback

0 0 upvotes · 0 downvotes
💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

Astroglial Gating of Microglial Ontogeny Switch
Score: 0.00 · P2RY12
CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Repro
Score: 0.00 · CCR2
CCR2-Mediated Microglial Replacement Drives mTOR-HIF1α Metabolic Repro
Score: 0.00 · CCR2
Astrocytic Metabolic Trained Immunity via AMPK-PGC1α Axis
Score: 0.00 · PRKAA1/PPARGC1A
Microglial Phenotypic Polarization via CSF1R-Mediated Metabolic Reprog
Score: 0.00 · CSF1R
→ View all analysis hypotheses